Nurix Therapeutics, Inc. NRIX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s financing cash flow?
- Nurix Therapeutics, Inc. (NRIX) reported financing cash flow of $19.98M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Nurix Therapeutics, Inc.'s financing cash flow increased by 1256.1% year-over-year, from $1.47M to $19.98M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s financing cash flow has grown at a 11.6% compound annual growth rate (CAGR), from $153.88M to $238.64M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.